Why did reported revenue decline if the business grew strongly?

The 4% revenue decline was driven by the expiration of a large customer contract (OptumRx), which contributed $9.8 billion of revenue in the prior-year quarter and none in the current quarter. Excluding that contract, revenue grew 16% to $55.3 billion, indicating robust underlying demand for brand and specialty pharmaceutical products.

Why did non-GAAP EPS grow only 2% when non-GAAP operating earnings grew 9%?

Non-GAAP interest and other expense increased sharply due to financing costs tied to the recent acquisitions, including the $2.9 billion of new debt. Net interest expense rose from $3 million to $35 million in the quarter, offsetting much of the operating earnings growth. A lower share count partly offset this effect.

What is driving the raised fiscal 2025 EPS guidance, and are there risks to it?

The raise to $7.85-$8.00 reflects stronger organic growth in Pharmaceutical and Specialty Solutions (segment profit growth guidance raised to 10%-12%) and contributions from GI Alliance and ION. Risks include the higher interest expense guidance, the GMPD segment profit reduction, ongoing pharmaceutical pricing and generic deflation uncertainty, and a Department of Justice investigation into potential Anti-Kickback Statute and False Claims Act violations.

Is the company's cash flow and balance sheet a concern for investors?

Operating cash flow was negative $2.0 billion year-to-date, largely due to inventory growth and lower accounts payable, compared with positive $1.7 billion a year earlier. Long-term obligations rose to $7.1 billion from $4.7 billion, and the shareholders' deficit was $2.9 billion. Investors should monitor whether working capital normalizes and how the company manages leverage following the acquisitions.

What were the main acquisition and strategic developments announced?

Cardinal Health completed its acquisition of a majority stake in GI Alliance, a gastroenterology management services organization with over 900 physicians across 345 locations, and closed the Integrated Oncology Network acquisition in December 2024. These deals support its Navista oncology platform and multi-specialty growth strategy. The company also began commercial-scale production of actinium-225 for theranostics.

CAH 8-K: Earnings & Results & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed January 30, 2025. Cited figures are marked; the original filing is the authoritative source.

Cardinal Health (CAH) reported second-quarter fiscal 2025 results (quarter ended December 31, 2024) alongside a raised full-year non-GAAP EPS outlook.

Consolidated revenue fell 4% to $55.3 billion^a, but this decline reflects the previously communicated expiration of a large customer contract (OptumRx); excluding that impact, revenue grew 16%. GAAP operating earnings rose 9% to $549 million and GAAP diluted EPS was $1.65 (up 10%). Non-GAAP operating earnings rose 9% to $635 million, led by the Pharmaceutical and Specialty Solutions segment, while non-GAAP diluted EPS grew only 2% to $1.93, held back by higher interest and other expense from acquisition financing.

Management raised fiscal 2025 non-GAAP diluted EPS guidance to $7.85^b-$8.00 from $7.75-$7.90, reflecting the completed acquisitions of Integrated Oncology Network and a majority stake in GI Alliance. Pharmaceutical and Specialty Solutions segment profit growth guidance was raised to 10%-12% from 4%-6%, while GMPD segment profit guidance was cut to $130-$150 million from $140-$175 million due to a second-quarter write-off of uncollectible receivables in the WaveMark business. Interest and other expense guidance was raised to $200-$230 million from $140-$170 million, driven by $2.9 billion in new debt financing.

Investors should weigh the strong underlying growth and guidance raise against balance sheet and cash flow considerations. Year-to-date operating cash flow was negative $2.0 billion^c (versus positive $1.7 billion a year earlier), driven by inventory build and payables timing, and non-GAAP adjusted free cash flow was negative $1.6 billion. Total debt rose from roughly $5.1 billion to $7.6 billion, and shareholders' deficit remained at $2.9 billion.

02—Key points

Key Highlights

Revenue declined 4% to $55.3 billion, but grew 16% excluding the expired large customer contract; Pharmaceutical and Specialty Solutions revenue grew 17% on the same basis.
GAAP diluted EPS rose 10% to $1.65; non-GAAP diluted EPS rose 2% to $1.93, held back by higher interest expense from acquisition financing.
Non-GAAP operating earnings increased 9% to $635 million, with Pharmaceutical and Specialty Solutions segment profit up 7% to $531 million.
Fiscal 2025 non-GAAP EPS guidance raised to $7.85-$8.00 from $7.75-$7.90, incorporating the ION and GI Alliance acquisitions.
GMPD segment profit guidance lowered to $130-$150 million from $140-$175 million after a WaveMark uncollectible receivables write-off.
Interest and other expense guidance raised to $200-$230 million from $140-$170 million following $2.9 billion in new debt issuance.
Year-to-date operating cash flow was negative $2.0 billion and non-GAAP adjusted free cash flow was negative $1.6 billion, versus positive results a year earlier.

03—Questions

Frequently Asked Questions

Why did reported revenue decline if the business grew strongly?
The 4% revenue decline was driven by the expiration of a large customer contract (OptumRx), which contributed $9.8 billion of revenue in the prior-year quarter and none in the current quarter. Excluding that contract, revenue grew 16% to $55.3 billion, indicating robust underlying demand for brand and specialty pharmaceutical products.
Why did non-GAAP EPS grow only 2% when non-GAAP operating earnings grew 9%?
Non-GAAP interest and other expense increased sharply due to financing costs tied to the recent acquisitions, including the $2.9 billion of new debt. Net interest expense rose from $3 million to $35 million in the quarter, offsetting much of the operating earnings growth. A lower share count partly offset this effect.
What is driving the raised fiscal 2025 EPS guidance, and are there risks to it?
The raise to $7.85-$8.00 reflects stronger organic growth in Pharmaceutical and Specialty Solutions (segment profit growth guidance raised to 10%-12%) and contributions from GI Alliance and ION. Risks include the higher interest expense guidance, the GMPD segment profit reduction, ongoing pharmaceutical pricing and generic deflation uncertainty, and a Department of Justice investigation into potential Anti-Kickback Statute and False Claims Act violations.
Is the company's cash flow and balance sheet a concern for investors?
Operating cash flow was negative $2.0 billion year-to-date, largely due to inventory growth and lower accounts payable, compared with positive $1.7 billion a year earlier. Long-term obligations rose to $7.1 billion from $4.7 billion, and the shareholders' deficit was $2.9 billion. Investors should monitor whether working capital normalizes and how the company manages leverage following the acquisitions.
What were the main acquisition and strategic developments announced?
Cardinal Health completed its acquisition of a majority stake in GI Alliance, a gastroenterology management services organization with over 900 physicians across 345 locations, and closed the Integrated Oncology Network acquisition in December 2024. These deals support its Navista oncology platform and multi-specialty growth strategy. The company also began commercial-scale production of actinium-225 for theranostics.

04—Continue

← View all 8-K filings